French drugmaker Roussel Uclaf has sold its self-medication products unit Soekami-Lefrancq to Hoffmann-La Roche. RU purchased the company in 1990 in the hope of expanding in the non-prescription drugs sector, but sales did not exceed 200 million French francs ($40.1 million) in 1994, with profits of 11 million francs. Roussel has decided to abandon its efforts because it lacks the critical size needed to make an impact in the market. Roche, in contrast, is already solidly implanted in the sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze